Abstract:M2 isomer of pyruvate kinase (PKM2), a key enzyme in aerobic glycolysis, is closely related to cancer development and progression. Suppression of PKM2 exhibits synergistic effects with docetaxel in lung cancer, but the therapeutic potential in colorectal cancer (CRC) is unclear. The aim of the present study was to explore the synergic effects and mechanism of knocking down PKM2 combined with oxaliplatin (a chemosensitizer) treatment in two CRC cell lines (HCT116 and DLD1). The PKM2 gene was initially knocked down using small interfering (si)RNAs (si155 and si156). Subsequently, the effects of PKM2-siRNAs and oxaliplatin, on CRC cells were determined using MTS, cell cycle analysis and apoptosis assays. The mechanism of targeting PKM2 was explored by detecting glucose uptake, lactate secretion fluxes, and the levels of glucose-6-phosphate dehydrogenase (G6PD) mRNA, glutathione (GSH) and reactive oxygen species (ROS). Cell viability in the experimental groups (PKM2-siRNAs, oxaliplatin, PKM2-siRNAs + oxaliplatin) was significantly reduced compared with the control group, and combination treatments (PKM2-siRNAs + oxaliplatin) were more effective than single treatments (PKM2-siRNAs and oxaliplatin only groups). Similar results were observed with the apoptosis assay. The combination groups showed synergistic effects compared with both single treatment groups. Furthermore, glucose uptake and lactate secretion and mRNA levels of G6PD and PKM2 were decreased after PKM2 knockdown in the PKM2-siRNAs and PKM2-siRNAs + oxaliplatin groups. The GSH levels in the PKM2-siRNAs group was significantly lower compared with the negative control group. The ROS levels in the PKM2-siRNAs groups were also significantly increased. The combination of PKM2-siRNAs and oxaliplatin had synergistic effects on CRC cells (HCT116 and DLD1). PKM2 silencing may alter energy metabolism in cancer cells and initiate ROS-induced apoptosis after downregulation of the pentose phosphate pathway by PKM2-siRNAs.

PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer

Knockdown of PKM2 enhances radiosensitivity of cervical cancer cells

High Expression of Pyruvate Kinase M2 is Associated with Chemosensitivity to Epirubicin and 5-Fluorouracil in Breast Cancer.

High expression of PKM2 as a poor prognosis indicator is associated with radiation resistance in cervical cancer

Efficacy and mechanism of combination of oxaliplatin with PKM2 knockdown in colorectal cancer

Overexpression of SMARCA2 or CAMK2D is Associated with Cisplatin Resistance in Human Epithelial Ovarian Cancer

Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin

PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma

PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma

Knockdown of PKM2 Enhances Radiosensitivity of Non-small Cell Lung Cancer

Targeting Pyruvate Kinase M2 Contributes to Radiosensitivity of Non-Small Cell Lung Cancer Cells in Vitro and in Vivo.

Enhanced Expression of PKM2 Associates with the Biological Properties of Cancer Stem Cells from A549 Human Lung Cancer Cells

PKM2–c-Myc–Survivin Cascade Regulates the Cell Proliferation, Migration, and Tamoxifen Resistance in Breast Cancer

The Role Of Pyruvate Kinase M2 In Anticancer Therapeutic Treatments

Knockdown of PRKD2 Enhances Chemotherapy Sensitivity in Cervical Cancer Via the TP53/CDKN1A Pathway.

Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics

PKM2 promotes cell migration and inhibits autophagy by mediating PI3K/AKT activation and contributes to the malignant development of gastric cancer

Increase in Cisplatin Resistance by MeCP2 in Human Gastric Cancer Through the Activation of the AKT Pathway by Facilitating PDK-1 Transcription

Pyruvate Kinase M2 Deregulation Enhances the Metastatic Potential of Tongue Squamous Cell Carcinoma

PKM2 Upregulation Promotes Malignancy and Indicates Poor Prognosis for Intrahepatic Cholangiocarcinoma.

Pyruvate Kinase Type M2 is Upregulated in Colorectal Cancer and Promotes Proliferation and Migration of Colon Cancer Cells.